Literature DB >> 23333074

Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.

Dietmar M W Zaiss1, Jorg van Loosdregt, Andrea Gorlani, Cornelis P J Bekker, Andrea Gröne, Maria Sibilia, Paul M P van Bergen en Henegouwen, Rob C Roovers, Paul J Coffer, Alice J A M Sijts.   

Abstract

Epidermal growth factor receptor (EGFR) is known to be critically involved in tissue development and homeostasis as well as in the pathogenesis of cancer. Here we showed that Foxp3(+) regulatory T (Treg) cells express EGFR under inflammatory conditions. Stimulation with the EGF-like growth factor Amphiregulin (AREG) markedly enhanced Treg cell function in vitro, and in a colitis and tumor vaccination model we showed that AREG was critical for efficient Treg cell function in vivo. In addition, mast cell-derived AREG fully restored optimal Treg cell function. These findings reveal EGFR as a component in the regulation of local immune responses and establish a link between mast cells and Treg cells. Targeting of this immune regulatory mechanism may contribute to the therapeutic successes of EGFR-targeting treatments in cancer patients.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23333074      PMCID: PMC3582723          DOI: 10.1016/j.immuni.2012.09.023

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  51 in total

Review 1.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

2.  Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy.

Authors:  Anna Johansson; Stina Rudolfsson; Peter Hammarsten; Sofia Halin; Kristian Pietras; Jonathan Jones; Pär Stattin; Lars Egevad; Torvald Granfors; Pernilla Wikström; Anders Bergh
Journal:  Am J Pathol       Date:  2010-07-08       Impact factor: 4.307

3.  Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.

Authors:  Karène Mahtouk; Dirk Hose; Thierry Rème; John De Vos; Michel Jourdan; Jérôme Moreaux; Geneviève Fiol; Marc Raab; Eric Jourdan; Véronique Grau; Marion Moos; Hartmut Goldschmidt; Marion Baudard; Jean François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Oncogene       Date:  2005-05-12       Impact factor: 9.867

4.  Mast cells are essential intermediaries in regulatory T-cell tolerance.

Authors:  Li-Fan Lu; Evan F Lind; David C Gondek; Kathy A Bennett; Michael W Gleeson; Karina Pino-Lagos; Zachary A Scott; Anthony J Coyle; Jennifer L Reed; Jacques Van Snick; Terry B Strom; Xin Xiao Zheng; Randolph J Noelle
Journal:  Nature       Date:  2006-08-20       Impact factor: 49.962

Review 5.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

Authors:  Robert L Ferris; Elizabeth M Jaffee; Soldano Ferrone
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

6.  Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers.

Authors:  Nobuhisa Ishikawa; Yataro Daigo; Atsushi Takano; Masaya Taniwaki; Tatsuya Kato; Satoshi Hayama; Haruyasu Murakami; Yukio Takeshima; Kouki Inai; Hitoshi Nishimura; Eiju Tsuchiya; Nobuoki Kohno; Yusuke Nakamura
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

7.  Amphiregulin production by human eosinophils.

Authors:  Kenji Matsumoto; Shuhei Fukuda; Yuri Nakamura; Hirohisa Saito
Journal:  Int Arch Allergy Immunol       Date:  2009-06-03       Impact factor: 2.749

8.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

9.  Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response.

Authors:  Nan Zhang; Bernd Schröppel; Girdhari Lal; Claudia Jakubzick; Xia Mao; Dan Chen; Na Yin; Rolf Jessberger; Jordi C Ochando; Yaozhong Ding; Jonathan S Bromberg
Journal:  Immunity       Date:  2009-03-20       Impact factor: 31.745

10.  Mast cells and eosinophils in invasive breast carcinoma.

Authors:  Rose-Marie Amini; Kirsimari Aaltonen; Heli Nevanlinna; Ricardo Carvalho; Laura Salonen; Päivi Heikkilä; Carl Blomqvist
Journal:  BMC Cancer       Date:  2007-08-29       Impact factor: 4.430

View more
  149 in total

1.  Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis.

Authors:  Sihua Wang; Yuan Zhang; Yan Wang; Ping Ye; Jun Li; Huabin Li; Qingqing Ding; Jiahong Xia
Journal:  J Biol Chem       Date:  2016-07-18       Impact factor: 5.157

Review 2.  Cytokines and costimulation in acute graft-versus-host disease.

Authors:  Geoffrey R Hill; Motoko Koyama
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

3.  Cancer Cell-targeted and Activatable Photoimmunotherapy Spares T Cells in a 3D Coculture Model.

Authors:  Eric M Kercher; Shubhankar Nath; Imran Rizvi; Bryan Q Spring
Journal:  Photochem Photobiol       Date:  2019-10-13       Impact factor: 3.421

Review 4.  Heterogeneity and Stability in Foxp3+ Regulatory T Cells.

Authors:  Booki Min
Journal:  J Interferon Cytokine Res       Date:  2017-07-11       Impact factor: 2.607

5.  Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus Erythematosus.

Authors:  Anniek Zaalberg; Sara Moradi Tuchayi; Amir H Ameri; Kenneth H Ngo; Trevor J Cunningham; Jean-Pierre Eliane; Maia Livneh; Thomas D Horn; Ilana S Rosman; Amy Musiek; Milan J Anadkat; Shadmehr Demehri
Journal:  J Invest Dermatol       Date:  2018-07-17       Impact factor: 8.551

6.  Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment.

Authors:  Andrew J Rech; Robert H Vonderheide
Journal:  Cancer Discov       Date:  2013-12       Impact factor: 39.397

7.  Foxp3-dependent transformation of human primary CD4+ T lymphocytes by the retroviral protein tax.

Authors:  Li Chen; Dan Liu; Yang Zhang; Huan Zhang; Hua Cheng
Journal:  Biochem Biophys Res Commun       Date:  2015-09-14       Impact factor: 3.575

8.  Epidermal growth factor receptor controls glycogen phosphorylase in T cells through small GTPases of the RAS family.

Authors:  Francisco Llavero; Miriam Luque Montoro; Alazne Arrazola Sastre; David Fernández-Moreno; Hadriano M Lacerda; Luis A Parada; Alejandro Lucia; José L Zugaza
Journal:  J Biol Chem       Date:  2019-01-15       Impact factor: 5.157

9.  Skin communicates what we deeply feel: antibiotic prophylactic treatment to reduce epidermal growth factor receptor inhibitors induced rash in lung cancer (the Pan Canadian rash trial).

Authors:  Oscar Arrieta; Amir Carmona; Maria Teresa de Jesus Vega; Mariana Lopez-Mejia; Andrés F Cardona
Journal:  Ann Transl Med       Date:  2016-08

10.  Allergic Sensitization Underlies Hyperreactive Antigen-Specific CD4+ T Cell Responses in Coincident Filarial Infection.

Authors:  Pedro H Gazzinelli-Guimarães; Sandra Bonne-Année; Ricardo T Fujiwara; Helton C Santiago; Thomas B Nutman
Journal:  J Immunol       Date:  2016-08-26       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.